Morimatsu (China) Investments, a wholly-owned subsidiary of Morimatsu International Holdings Co. Ltd., has been actively engaged in investment holding business within the People's Republic of China. The company recently participated in a significant transaction involving the Target Company, a non-wholly owned subsidiary. The Target Company, known for serving industries such as pharmaceuticals, biopharmaceuticals, and fast-moving consumer goods, is set to receive an additional registered capital of RMB12,946,412. This capital infusion, amounting to RMB330,000,000, was agreed upon through a transaction with investors, highlighting Morimatsu (China) Investments' ongoing commitment to supporting its subsidiaries in expanding their industry presence and capabilities.
免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。